See more : TransCoastal Corporation (TCEC) Income Statement Analysis – Financial Results
Complete financial analysis of Arcadia Biosciences, Inc. (RKDA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arcadia Biosciences, Inc., a leading company in the Agricultural Inputs industry within the Basic Materials sector.
You may be interested
- Shinsei Bank, Limited (SKLKY) Income Statement Analysis – Financial Results
- Maxnerva Technology Services Limited (1037.HK) Income Statement Analysis – Financial Results
- Envestnet, Inc. (ENV) Income Statement Analysis – Financial Results
- Money3 Corporation Limited (MNY.AX) Income Statement Analysis – Financial Results
- Skechers U.S.A., Inc. (SKX) Income Statement Analysis – Financial Results
Arcadia Biosciences, Inc. (RKDA)
About Arcadia Biosciences, Inc.
Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The company was incorporated in 2002 and is headquartered in Davis, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.33M | 9.96M | 6.78M | 8.03M | 1.17M | 1.46M | 4.03M | 3.19M | 5.41M | 6.98M | 6.48M | 7.01M |
| Cost of Revenue | 3.30M | 9.80M | 8.71M | 5.20M | 885.00K | 661.00K | 283.00K | 895.00K | 892.00K | 2.00M | 673.00K | 909.00K |
| Gross Profit | 2.03M | 154.00K | -1.93M | 2.84M | 284.00K | 803.00K | 3.74M | 2.29M | 4.52M | 4.99M | 5.81M | 6.10M |
| Gross Profit Ratio | 38.09% | 1.55% | -28.44% | 35.29% | 24.29% | 54.85% | 92.97% | 71.93% | 83.52% | 71.40% | 89.61% | 87.03% |
| Research & Development | 1.39M | 1.51M | 3.89M | 7.96M | 7.10M | 6.07M | 7.41M | 8.66M | 8.97M | 10.01M | 8.40M | 7.95M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 16.47M | 13.57M | 11.60M | 10.65M | 12.25M | 11.12M | 10.13M | 7.97M | 8.28M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.51M | 18.05M | 22.94M | 16.47M | 13.57M | 11.60M | 10.65M | 12.25M | 11.12M | 10.13M | 7.97M | 8.28M |
| Other Expenses | 73.00K | 33.00K | 10.11M | 105.00K | 466.00K | -3.61M | 281.00K | 340.00K | 521.00K | 0.00 | 5.00K | 8.00K |
| Operating Expenses | 15.90M | 19.56M | 26.83M | 24.43M | 20.67M | 17.67M | 18.06M | 20.91M | 20.09M | 20.14M | 16.37M | 16.23M |
| Cost & Expenses | 19.27M | 29.36M | 35.54M | 29.63M | 21.55M | 18.33M | 18.34M | 21.81M | 20.98M | 22.14M | 17.04M | 17.14M |
| Interest Income | 695.00K | 289.00K | 20.00K | 47.00K | 5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 289.00K | 20.00K | 47.00K | 5.00K | 0.00 | 747.00K | 1.32M | 2.66M | 1.39M | 626.00K | 186.00K |
| Depreciation & Amortization | 287.00K | 1.36M | 1.04M | 662.00K | 194.00K | 154.00K | 279.00K | 304.00K | 294.00K | 358.00K | 391.00K | 378.00K |
| EBITDA | -13.58M | -13.65M | -23.27M | -5.44M | -28.67M | -13.32M | -14.66M | -17.98M | -14.98M | -15.39M | -10.17M | -9.74M |
| EBITDA Ratio | -254.75% | -228.21% | -270.87% | -259.21% | -1,747.56% | -1,562.64% | -341.65% | -563.86% | -272.40% | -211.90% | -156.99% | -139.00% |
| Operating Income | -13.94M | -19.40M | -35.53M | -21.59M | -20.38M | -16.87M | -14.32M | -18.62M | -15.56M | -15.15M | -10.57M | -10.13M |
| Operating Income Ratio | -261.50% | -194.89% | -523.98% | -268.76% | -1,743.46% | -1,152.32% | -355.56% | -584.07% | -287.46% | -217.03% | -163.11% | -144.51% |
| Total Other Income/Expenses | 781.00K | 3.19M | 19.39M | 6.63M | -9.49M | 3.40M | -1.37M | -979.00K | -2.37M | -1.99M | -621.00K | -178.00K |
| Income Before Tax | -13.16M | -15.60M | -16.13M | -6.15M | -28.87M | -13.47M | -15.68M | -19.60M | -17.93M | -17.14M | -11.19M | -10.31M |
| Income Before Tax Ratio | -246.85% | -156.67% | -237.94% | -76.55% | -2,469.72% | -920.08% | -389.49% | -614.77% | -331.18% | -245.55% | -172.69% | -147.05% |
| Income Tax Expense | 8.00K | 14.00K | 2.00K | -124.00K | 2.00K | 10.00K | 26.00K | 25.00K | 26.00K | 263.00K | 167.00K | 213.00K |
| Net Income | -13.98M | -15.61M | -16.13M | -6.03M | -28.87M | -13.48M | -15.71M | -19.62M | -17.96M | -18.34M | -13.20M | -12.37M |
| Net Income Ratio | -262.31% | -156.81% | -237.96% | -75.01% | -2,469.89% | -920.77% | -390.14% | -615.56% | -331.66% | -262.66% | -203.69% | -176.46% |
| EPS | -11.30 | -26.05 | -30.33 | -24.20 | -181.50 | -143.16 | -291.38 | -353.85 | -503.00 | -448.39 | -322.62 | -302.44 |
| EPS Diluted | -11.30 | -26.05 | -30.33 | -24.20 | -181.50 | -143.16 | -291.38 | -353.85 | -503.00 | -448.39 | -322.62 | -302.44 |
| Weighted Avg Shares Out | 1.24M | 599.39K | 532.02K | 248.98K | 159.08K | 94.16K | 53.91K | 55.46K | 35.70K | 40.90K | 40.90K | 40.90K |
| Weighted Avg Shares Out (Dil) | 1.24M | 599.39K | 532.02K | 248.98K | 159.08K | 94.16K | 53.91K | 55.46K | 35.70K | 40.90K | 40.90K | 40.90K |
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Arcadia Biosciences, Inc. - RKDA
NEW YORK , Dec. 6, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Arcadia Biosciences, Inc.
NEW YORK , Dec. 6, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Arcadia Biosciences, Inc. (NASDAQ: RKDA) and its board of directors concerning the proposed acquisition of the company by Roosevelt Resources LP. Arcadia stockholders...
Shareholder Alert: Ademi LLP investigates whether Arcadia Biosciences, Inc. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Arcadia (NASDAQ: RKDA) for possible breaches of fiduciary duty and other violations of law in its transaction with Roosevelt Resources. Click here to learn how to join our investigation and obtain additional information or contact...
RKDA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Arcadia Biosciences, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Arcadia Biosciences, Inc. (NASDAQ: RKDA) and Roosevelt Resources LP is fair to Arcadia shareholders. Upon closing of the proposed transaction, Arcadia shareholders are expected...
Arcadia Biosciences (RKDA) Enters Into Business Combination Agreement with Roosevelt Resources in All-Stock Transaction
DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA) and Roosevelt Resources LP announced today that they have entered into a definitive securities exchange agreement which, when completed, will combine the two companies in an all-stock transaction. Under the terms of the agreement,...
Arcadia Biosciences' Q3 Earnings Miss Estimates, Sales Increase Y/Y
RKDA witnesses a solid 55% improvement in Zola sales in Q3. The company continues to invest to grow the Zola brand.
Arcadia Biosciences (RKDA) Reports Q3 Loss, Tops Revenue Estimates
Arcadia Biosciences (RKDA) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to loss of $1.83 per share a year ago.
Arcadia Biosciences, Inc. (RKDA) Q3 2024 Earnings Call Transcript
Arcadia Biosciences, Inc. (NASDAQ:RKDA ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Mark Kawakami - Chief Financial Officer T.J. Schaefer - President & Chief Executive Officer Conference Call Participants Ben Klieve - Lake Street...
Arcadia Biosciences (RKDA) Announces Date of Third Quarter 2024 Financial Results and Business Highlights Conference Call
DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial and business results for the third quarter of 2024 after market close on November 12,...
4 Agriculture - Products Stocks to Watch Despite Industry Concerns
The near-term outlook for the Zacks Agriculture - Products industry is uncertain due to low commodity prices and inflated costs. Investors should watch BG, WFG, HYFM and RKDA, which are braving the industry headwinds.
Source: https://incomestatements.info
Category: Stock Reports